CTIS2022-501522-38-00RecruitingPhase 1
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial - M19-388
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 165
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •Subject has completed a prior venetoclax study, and the investigator believes that continued treatment with venetoclax is in the best interest of the patient., Subjects are willing or able to comply with procedures required in this protocol., Subjects entering the extension study with multiple myeloma must adhere to the following guidelines: • All subjects receiving treatment with venetoclax in combination with a proteasome inhibitor must receive prophylaxis with antibiotics while on treatment and for at least 30 days after discontinuation of the proteasome inhibitor and/or venetoclax including: Bactrim forte® (1 tablet, 3 times a week) or equivalent antibiotic therapy AND Amoxicillin clavulanate (500 mg to 1 g, twice daily) or levofloxacin (500 mg once daily, adjusted for renal function) or equivalent antibiotic therapy per institutional guidelines, Subjects or their legally authorized representative must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures., Subjects agree to abide by protocol-mandated pregnancy avoidance measures.
Exclusion Criteria
- •Female who is pregnant, breastfeeding, or considering becoming pregnant during the study and for approximately 30 days after the last dose of study drug., Male who is considering fathering a child or donating sperm during the study and for approximately 90 days after the last dose of study drug., Subjects receiving any live vaccines during study participation including until at least 4 weeks (for all indications except MM) and 8 weeks (for subjects with MM) after the last dose of study drug.
Investigators
Similar Trials
Active, not recruiting
Phase 1
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialMultiple MyelomaEUCTR2018-004356-38-SEAbbVie Deutschland GmbH & Co. KG550
Active, not recruiting
Phase 1
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialMultiple MyelomaEUCTR2018-004356-38-ATAbbVie Deutschland GmbH & Co. KG550
Active, not recruiting
Phase 1
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialChronic lymphocytic leukemiaNon-Hodgkin's lymphomaT prolymphocytic leukemiaChronic myeloid leukemiaWaldenstrom's macroglobulinemia lymphoma and Relapsed/refractory pediatric malignanciesAcute Myelogenous Leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2018-004356-38-DKAbbVie Deutschland GmbH & Co. KG550
Active, not recruiting
Phase 1
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialChronic lymphocytic leukemiaNon-Hodgkin's lymphomaT prolymphocytic leukemiaChronic myeloid leukemiaWaldenstrom's macroglobulinemia lymphoma and Relapsed/refractory pediatric malignanciesAcute Myelogenous Leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2018-004356-38-PLAbbVie Deutschland GmbH & Co. KG550
Active, not recruiting
Phase 1
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialMultiple MyelomaEUCTR2018-004356-38-GRAbbVie Deutschland GmbH & Co. KG550